Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070770 | 1.00 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL658385 | 1.00 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL658386 | 1.00 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL5808152 | 0.83 | — | — | |
| SCHEMBL657746 | 0.83 | — | — | |
| SCHEMBL658701 | 0.83 | — | — | |
| SCHEMBL466156 | 0.83 | — | — | |
| SCHEMBL466051 | 0.83 | — | — | |
| SCHEMBL660076 | 0.83 | — | — | |
| SCHEMBL466052 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | claimed |
| EP-2260839-A2 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | Merz Pharma GmbH & Co. KGaA (DE) | 2010-12-15 | — | — | EP | claimed |
| EP-1682109-B1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-10-15 | — | — | EP | claimed |
| US-20070082956-A1 | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity. | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-04-12 | — | — | US | claimed |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | FOREST LABORATORIES, INC. (US) | 2006-09-14 | — | — | US | claimed |
| EP-1682109-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | Merz Pharma GmbH & Co. KGaA (DE) | 2006-07-26 | — | — | EP | claimed |
| EP-1660058-A2 | THE USE OF 1-AMINO-ALKYLCYCLOHEXANE COMPOUNDS IN THE TREATMENT OF PAIN HYPERSENSITIVITY | Merz Pharma GmbH & Co. KGaA (DE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005079779-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-01 | — | — | WO | claimed |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | FOREST LABORATORIES, INC. (US) | 2005-05-26 | — | — | US | claimed |
| WO-2005009421-A2 | THE USE OF 1-AMINO-ALKYLCYCLOHEXANE COMPOUNDS IN THE TREATMENT OF PAIN HYPERSENSITIVITY | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-02-03 | — | — | WO | claimed |
| EP-1318800-B1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2005-01-26 | — | — | EP | claimed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | claimed |
| US-6602862-B1 | 1-Amino-alkylcyclohexanes as trypanocidal agents | MERZ PHARMA GMBH & CO., KGAA (DE) | 2003-08-05 | — | — | US | claimed |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170027885-A1 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2017-02-02 | — | — | US | disclosed |
| EP-1318800-B1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2005-01-26 | — | — | EP | disclosed |
| US-20050014743-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | FOREST LABORATORIES, INC. (US) | 2005-01-20 | — | — | US | disclosed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | disclosed |
| US-6602862-B1 | 1-Amino-alkylcyclohexanes as trypanocidal agents | MERZ PHARMA GMBH & CO., KGAA (DE) | 2003-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082956-A1 | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity. | GRIN1, OPRL1, GRIN3A | NOS3 3422/4885NOS1 1609/4885NOS2 3280/4885 |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | NOS3 3210/4885NOS1 1030/4885NOS2 2333/4885 |
| US-20170027885-A1 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS | OTC, CNR2, CNR1 | NOS3 3149/4885NOS1 2475/4885NOS2 2513/4885 |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | APP, BACE1, PSEN1 | NOS3 3446/4885NOS1 1407/4885NOS2 2242/4885 |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | NOS3 3251/4885NOS1 3305/4885NOS2 3430/4885 |
| US-20050014743-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | GRIN2A, GRIN2B, GRIN3B | NOS3 1803/4885NOS1 1474/4885NOS2 1973/4885 |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | NMBR, NMUR1, CNR1 | NOS3 3060/4885NOS1 1583/4885NOS2 2833/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | NOS3 1968/4885NOS1 535/4885NOS2 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.